EyePoint (EYPT) Other Accumulated Expenses (2012 - 2026)
EyePoint (EYPT) reported Other Accumulated Expenses of $701000.0 for Q1 2026, down 64.33% on a YoY basis from $2.0 million in Q1 2025, and down 67.24% sequentially from $2.1 million in Q4 2025.
EyePoint (EYPT) Other Accumulated Expenses (2012 - 2026) Analysis & Trends
EyePoint (EYPT) has 15 years of Other Accumulated Expenses data on file, last reported at $701000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Accumulated Expenses fell 64.33% year-over-year to $701000.0; the trailing twelve-month figure through Mar 2026 stood at $701000.0 (down 64.33% YoY), and the FY2025 full-year result was $2.1 million, up 48.61% from the prior year.
- Other Accumulated Expenses eased to $701000.0 in Q1 2026, from $2.1 million in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $2.1 million in Q4 2025 to a low of $183000.0 in Q3 2023.
- A 5-year average of $882529.4 and a median of $753000.0 in 2025 frame the typical range for Other Accumulated Expenses.
- Across the five-year window, Other Accumulated Expenses sank 74.73% in 2023 and soared 761.84% in 2025, its largest moves.
- Tracing EYPT's Other Accumulated Expenses over 5 years: stood at $1.8 million in 2022, then plunged by 63.25% to $646000.0 in 2023, then soared by 122.91% to $1.4 million in 2024, then surged by 48.61% to $2.1 million in 2025, then slumped by 67.24% to $701000.0 in 2026.
- Business Quant data shows EYPT's Other Accumulated Expenses at $701000.0 in Q1 2026, $2.1 million in Q4 2025, and $434000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 472.40 Bn | 467.61 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.23 Bn | 114.98 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn |
| 10 | EyePoint | 1.07 Mn | -221.48 Mn | 168,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 701,000.00 |
| Dec 31, 2025 | 2.14 Mn |
| Sep 30, 2025 | 434,000.00 |
| Jun 30, 2025 | 753,000.00 |
| Mar 31, 2025 | 1.97 Mn |
| Dec 31, 2024 | 1.44 Mn |
| Sep 30, 2024 | 434,000.00 |
| Jun 30, 2024 | 1.13 Mn |
| Mar 31, 2024 | 228,000.00 |
| Dec 31, 2023 | 646,000.00 |
| Sep 30, 2023 | 183,000.00 |
| Jun 30, 2023 | 234,000.00 |
| Mar 31, 2023 | 772,000.00 |
| Dec 31, 2022 | 1.76 Mn |
| Sep 30, 2022 | 496,000.00 |
| Jun 30, 2022 | 926,000.00 |
| Mar 31, 2022 | 763,000.00 |
| Dec 31, 2021 | 1.14 Mn |
| Sep 30, 2021 | 1.41 Mn |
| Jun 30, 2021 | 707,000.00 |